1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Elite Pharmaceuticals, Inc. (ELTP) - Financial and Strategic SWOT Analysis Review

Elite Pharmaceuticals, Inc. (ELTP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company focuses on the development of oral sustained and controlled release products. Elite develops its products in the areas of pain management, cardiovascular, infection and allergy. The company focuses on developing the improved versions of off-patented drugs for life cycle management and generic versions of controlled release drug products which have high barriers for entry. Its product portfolio includes phentermine 37.5mg tablets, Lodrane D, methadone 10mg tablets and hydromorphone hydrochloride 8mg tablets, among others, which are commercialized products either owned, licensed or contract manufactured. The company also pipeline of abuse-deterrent opioids for the treatment of chronic pain. Its in-house capabilities include product development of oral solid dosage forms, clinical batch manufacturing, and GMP manufacturing facilities which provides its proprietary technology a strong base. Elite is headquartered in New Jersey, the US.

Elite Pharmaceuticals, Inc. Key Recent Developments

Aug 09, 2016: Elite Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2017
May 04, 2016: Elite Pharmaceuticals Appoints Davis S. Caskey to Its Board of Directors
Apr 12, 2016: Elite Pharmaceuticals Announces Changes to their Board of Directors
Jan 13, 2016: Nasrat Hakim Named Chairman Of Board Of Directors For Elite Pharmaceuticals
Nov 09, 2015: Elite Pharmaceuticals Reports Strong Growth for Second Quarter of Fiscal Year 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Elite Pharmaceuticals, Inc. (ELTP) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2


Section 1 - About the Company 6
Elite Pharmaceuticals, Inc. - Key Facts 6
Elite Pharmaceuticals, Inc. - Key Employees 7
Elite Pharmaceuticals, Inc. - Key Employee Biographies 8
Elite Pharmaceuticals, Inc. - Major Products and Services 9
Elite Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data 10
Elite Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Elite Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Elite Pharmaceuticals, Inc. - History 13
Elite Pharmaceuticals, Inc. - Company Statement 16
Elite Pharmaceuticals, Inc. - Locations And Subsidiaries 17
Head Office 17
Other Locations and Subsidiaries 17
Section 2 - Company Analysis 18
Elite Pharmaceuticals, Inc. - Business Description 18
Elite Pharmaceuticals, Inc. - Corporate Strategy 19
Elite Pharmaceuticals, Inc. - SWOT Analysis 20
SWOT Analysis - Overview 20
Elite Pharmaceuticals, Inc. - Strengths 20
Strength - Patent Portfolio 20
Strength - Strategic Collaborations 20
Strength - Portfolio of Abuse-Deterrent Products 20
Elite Pharmaceuticals, Inc. - Weaknesses 21
Weakness - Termination of Agreement 21
Weakness - History of Losses 21
Elite Pharmaceuticals, Inc. - Opportunities 22
Opportunity - Strong Product Pipeline 22
Opportunity - Product Launches 22
Opportunity - Market Potential for Pain Treatments 22
Elite Pharmaceuticals, Inc. - Threats 23
Threat - Intense Competition 23
Threat - Stringent Governmental Regulations 23
Threat - Uncertain RandD Outcomes 23
Elite Pharmaceuticals, Inc. - Key Competitors 24
Section 3 - Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 - Company's Lifesciences Financial Deals and Alliances 31
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 31
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 32
Elite Pharmaceuticals, Inc., Recent Deals Summary 33
Section 5 - Company's Recent Developments 34
Aug 09, 2016: Elite Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2017 34
May 04, 2016: Elite Pharmaceuticals Appoints Davis S. Caskey to Its Board of Directors 35
Apr 12, 2016: Elite Pharmaceuticals Announces Changes to their Board of Directors 36
Jan 13, 2016: Nasrat Hakim Named Chairman Of Board Of Directors For Elite Pharmaceuticals 37
Nov 09, 2015: Elite Pharmaceuticals Reports Strong Growth for Second Quarter of Fiscal Year 2016 38
Aug 10, 2015: Elite Pharmaceuticals Reports Record Revenues For First Quarter Of Fiscal Year 2016 39
Jun 16, 2015: Elite Pharmaceuticals Granted New Patent For Abuse Deterrent Technology 40
Jun 15, 2015: Elite Pharmaceuticals Reports Financial Results for the Fiscal Year Ended March 31, 2015 41
Feb 17, 2015: Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2015 42
Section 6 - Appendix 43
Methodology 43
Ratio Definitions 43
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Elite Pharmaceuticals, Inc., Key Facts 6
Elite Pharmaceuticals, Inc., Key Employees 7
Elite Pharmaceuticals, Inc., Key Employee Biographies 8
Elite Pharmaceuticals, Inc., Major Products and Services 9
Elite Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 10
Elite Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 11
Elite Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 12
Elite Pharmaceuticals, Inc., History 13
Elite Pharmaceuticals, Inc., Subsidiaries 17
Elite Pharmaceuticals, Inc., Key Competitors 24
Elite Pharmaceuticals, Inc., Ratios based on current share price 25
Elite Pharmaceuticals, Inc., Annual Ratios 26
Elite Pharmaceuticals, Inc., Interim Ratios 29
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 31
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 32
Elite Pharmaceuticals, Inc., Recent Deals Summary 33
Currency Codes 43
Capital Market Ratios 43
Equity Ratios 44
Profitability Ratios 44
Cost Ratios 45
Liquidity Ratios 45
Leverage Ratios 46
Efficiency Ratios 46

List of Figures
Elite Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Elite Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Elite Pharmaceuticals, Inc., Performance Chart (2012 - 2016) 28
Elite Pharmaceuticals, Inc., Ratio Charts 30
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 31
Elite Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals by Type, 2010 to YTD 2016 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.